trending Market Intelligence /marketintelligence/en/news-insights/trending/IOstm0sEUP426nqxEuJhjA2 content esgSubNav
In This List

Sanofi secures rights to cancer biosimilar for Chinese market

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Sanofi secures rights to cancer biosimilar for Chinese market

Sanofi is partnering with JHL Biotech Inc. to develop and commercialize biological therapeutics for the Chinese market.

Sanofi will invest US$80 million in the Taiwan-based biopharmaceutical company and pay a further US$21 million to secure rights to JHL's proposed biosimilar of Rituximab, a drug used to treat certain types of cancers.

JHL Biotech will be responsible for developing and registering the biosimilar while Sanofi will head commercialization in China.

In addition to sales royalties, JHL Biotech will also be eligible to receive up to US$236 million in milestone payments as a result of the deal.